Prognostic Factors for Pancreatic Cancer Patients Treated with Immune-cell Therapy

The past 17 years, immune-cell therapy has been administered to 990 patients with advanced or recurrent pancreatic adenocarcinoma and 50 patients with curatively resected pancreatic adenocarcinoma. The correlation between overall survival (OS) and various factors including sex, age, performance stat...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2018-07, Vol.38 (7), p.4353-4360
Main Authors: Makita, Kaori, Kamigaki, Takashi, Okada, Sachiko, Matsuda, Eriko, Ibe, Hiroshi, Oguma, Eri, Naitoh, Keiko, Takimoto, Rishu, Goto, Shigenori
Format: Article
Language:English
Subjects:
Adenocarcinoma
Adenocarcinoma - mortality
Adenocarcinoma - therapy
Adult
Aged
Aged, 80 and over
Cancer
Cancer Vaccines - therapeutic use
Chemotherapy
Combined vaccines
Confidence intervals
Dendritic cells
Dendritic Cells - transplantation
Disease-Free Survival
Female
Humans
Kaplan-Meier Estimate
Lymphocytes
Lymphocytes T
Male
Medical prognosis
Metastases
Metastasis
Middle Aged
Multivariate analysis
Pancreatic cancer
Pancreatic Neoplasms
Pancreatic Neoplasms - mortality
Pancreatic Neoplasms - therapy
Patients
Prognosis
Proportional Hazards Models
Radiation therapy
Retrospective Studies
Survival
T-Lymphocytes - transplantation
Treatment Outcome
Vaccines
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The past 17 years, immune-cell therapy has been administered to 990 patients with advanced or recurrent pancreatic adenocarcinoma and 50 patients with curatively resected pancreatic adenocarcinoma. The correlation between overall survival (OS) and various factors including sex, age, performance status (PS), distant metastasis, chemotherapy, radiotherapy, and type of immune-cell therapy were evaluated by univariate and multivariate analyses. The median OS of advanced or recurrent pancreatic cancer was 5.8 months, and the prognosis was improved in pancreatic cancer patients who received immune-cell therapy with PS scores of 0-1 [hazard risk (HR)=0.56; 95% confidence interval (CI)=0.46-0.68; p
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.12736